Uniformed Services University of the Health Sciences
4301 Jones Bridge Road
Bethesda, Maryland 20814
Molecular and cellular mechanisms of Physiology and Biochemistry of the heart, brain, and circulation in health, disease. Reversible vs. irreversible cell/organ damage: cardiac stunning, hibernation, infarct, necrosis and apoptosis (programmed cell death). Linking molecular, cellular and systemic physiological mechanisms. Pursuit of interdisciplinary efforts to combine holistic and reductionistic approaches to elucidate cellular physiological and molecular mechanisms in health and disease. Develop the therapeutic potential of metabolic interventions as distinct from pharmacologically based signal transduction and molecular genetic engineering. One of our ongoing efforts has been to improve therapeutic regimens currently used in heart lung bypass procedures and hemorrhagic shock. The fundamental concept is that it should be feasible to metabolically protect the myocardium as well as other high-energy-turnover tissues (brain, kidney, liver) and perhaps the organism as a whole using appropriate metabolic as opposed to traditional medical or pharmacological interventions. We are looking at metabolic strategies that can set cellular redox states and energy potentials in such away that the specific cell function becomes better sustainable and more robust during periods of acute stress such as hypoxemia, ischemia, reperfusion, catecholamine or other toxicities including humoral complement activation, oxidative stress and recovery there from. Currently we are focusing on two natural compounds that appear to satisfy, in part, these requirements: pyruvate, a non-receptor-linked glycolytic metabolite, and adenosine, a vasoactive ATP catabolite that serves also as precursor of the vital cellular adenylates and is a ligand at purinergic receptors throughout the body, heart and brain in particular.
Shock/resuscitation research may lead to more efficient use of limited blood banking resources under field conditions. The metabolic intervention has the potential of becoming a useful adjunct regimen for existing parenteral medical and pharmacological procedures in clinical medicine emergency scenarios.
US Patent # 5,714,515 licensed to RTS industries in 1999, Ronald T. Stanko CEO. (Patent expires in 2014)
American Journal of Physiology, Heart and Circulation, since 1999
North American and European funding institutions: including NIH, NSF, NASA, Veterans Administration, U.S. Army Medical Research and Development, NATO, Dutch Heart Foundation, Canadian Research Council, Human Frontier Science Program of France, Italian Space Agency. American and European Biomedical Journals: Circulation, Cardiovascular Research, American Journal Of Physiology, Circulation Research, British Journal Of Pharmacology and many other biomedical Research Journals
Sixty nine national and international invited presentations and lectures
In: Textbook of Angiology: R. Bünger, P. Gwirtz: Coronary Vasculature and Endothelium. Editor: J.B. Chang, Long Island Vascular Center, New York. Springer Verlag 1999
In: The heart and cardiovascular system, vol I, 2nd edition. R.A. Olsson, R. Bünger, J.A.E. Spann: Coronary Circulation. Fozard, H.A., Haber, E., Jennings, R.B., Katz, A.M., Morgan, H.E., eds.; Raven Press, New York, pp 1391-1426, 1991
In: Myocardial Energy Metabolism. R. Bünger, RT MALLET, DA HARTMAN: Redox manipulation of cytosolic phosphorylation potential and purine nucleoside release in perfused working heart. Martinus Nijhoff. The NETHERLANDS. J.W. deJong, ed., pp. 67-81, Dordrecht/Boston/Lancaster 1988
In: Progress in Cardiovasc Diseases. 29, 369-387,1987. R.A. Olsson, R. Bünger: Metabolic control of coronary flow.